Iovance Biotherapeutics
IOVA
87 hedge funds and large institutions have $461M invested in Iovance Biotherapeutics in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 24 reducing their positions, and 12 closing their positions.
173% more call options, than puts
Call options by funds: $942K | Put options by funds: $345K
38% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 24
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
7% more capital invested
Capital invested by funds: $429M → $461M (+$32M)
2% more funds holding
Funds holding: 85 → 87 (+2)
2.27% more ownership
Funds ownership: 77.09% → 79.36% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$8.45M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$8.2M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.16M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.19M |
| 5 |
QF
QVT Financial
New York
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$11.5M |
| 2 |
O
OrbiMed
New York
|
-$7.04M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.24M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$4.31M |
| 5 |
JP Morgan Chase
New York
|
-$4.14M |
IOVA Hedge Fund Activity: Q4 2017 in Review
87 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2017, worth a combined $461M — up 7.5% from $429M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IOVA positions and 12 closed out — a net gain of 2 holders — while 33 added to existing stakes and 24 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $8.45M. The largest seller was Millennium Management, cutting an estimated $11.5M.
- 87 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2017, up from 85 in Q3 2017.
- Funds reported $461M of Iovance Biotherapeutics stock for Q4 2017, up 7.5% quarter-over-quarter.
- 14 funds opened new Iovance Biotherapeutics positions in Q4 2017 and 12 closed out, a net change of +2 holders.
- The largest Iovance Biotherapeutics buyer in Q4 2017 was Avoro Capital Advisors, an estimated $8.45M added.
- The largest Iovance Biotherapeutics seller in Q4 2017 was Millennium Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q4 2017.